Shaanxi Academy of Traditional Chinese Medicine (Shaanxi Traditional Chinese Medicine Hospital), Xi'an, 710003, PR China.
Shaanxi Academy of Traditional Chinese Medicine (Shaanxi Traditional Chinese Medicine Hospital), Xi'an, 710003, PR China.
J Ethnopharmacol. 2023 Jan 30;301:115749. doi: 10.1016/j.jep.2022.115749. Epub 2022 Sep 29.
Atherosclerosis (AS) is a common systemic disease with increasing morbidity and mortality worldwide. Traditional Chinese medicine (TCM) with characteristics of multiple pathways and targets, presents advantages in the diagnosis and treatment of atherosclerosis.
With the modernization of TCM, the active ingredients and molecular mechanisms of TCM for AS treatment have been gradually revealed. Therefore, it is necessary to examine the existing studies on TCM therapies aimed at regulating AS over the past two decades.
Using "atherosclerosis" and "Traditional Chinese medicine" as keywords, all relevant TCM literature published in the last 10 years was collected from electronic databases (such as Elsevier, Springer, PubMed, CNKI, and Web of Science), books and papers until March 2022, and the critical information was statistically analyzed.
In this review, we highlighted extracts of 8 single herbs, a total of 41 single active ingredients, 20 TCM formulae, and 25 patented drugs, which were described with chemical structure, source, model, efficacy and potential mechanism.
We summarized the cytopathological basis for the development of atherosclerosis involving vascular endothelial cells, macrophages and vascular smooth muscle cells, and categorically elaborated the medicinal TCM used for AS, all of which provide the current evidence on the better management of atherosclerosis by TCM.
动脉粥样硬化(AS)是一种常见的全身性疾病,在全球范围内发病率和死亡率不断上升。中医(TCM)具有多途径、多靶点的特点,在动脉粥样硬化的诊断和治疗方面具有优势。
随着中医现代化,TCM 治疗动脉粥样硬化的活性成分和分子机制逐渐被揭示。因此,有必要对过去 20 年来针对 AS 治疗的 TCM 疗法的现有研究进行评估。
使用“动脉粥样硬化”和“中医”作为关键词,从电子数据库(如 Elsevier、Springer、PubMed、CNKI 和 Web of Science)、书籍和论文中收集过去 10 年发表的所有相关 TCM 文献,直到 2022 年 3 月,并对关键信息进行了统计分析。
在本次综述中,我们重点介绍了 8 种单味草药、41 种单味活性成分、20 种中药方剂和 25 种专利药物的提取物,其中包括化学结构、来源、模型、功效和潜在机制。
我们总结了涉及血管内皮细胞、巨噬细胞和血管平滑肌细胞的动脉粥样硬化发展的细胞病理学基础,并对用于 AS 的药用 TCM 进行了分类阐述,为 TCM 更好地治疗动脉粥样硬化提供了当前证据。